Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis …
RR Razonable, A Rivero, A Rodriguez… - The Journal of …, 2001 - academic.oup.com
The natural history of cytomegalovirus (CMV) disease associated with solid organ
transplantation has been modified as a result of the widespread use of antiviral prophylaxis …
transplantation has been modified as a result of the widespread use of antiviral prophylaxis …
Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants
E Meijer, GJ Boland, LF Verdonck - Clinical microbiology reviews, 2003 - Am Soc Microbiol
The main risk factors for cytomegalovirus (CMV) disease in recipients of allogeneic stem cell
transplants (SCT) are recipient CMV seropositivity and acute graft-versus-host disease …
transplants (SCT) are recipient CMV seropositivity and acute graft-versus-host disease …
Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real‐world evidence
AD Raval, KD Kistler, Y Tang, Y Murata… - Transplant Infectious …, 2021 - Wiley Online Library
Kidney transplant recipients (KTRs) have increased risk for cytomegalovirus (CMV)
infection/disease given the necessity of drug‐induced immunosuppression. A …
infection/disease given the necessity of drug‐induced immunosuppression. A …
[HTML][HTML] Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy
AC Kalil, AG Freifeld, ER Lyden, JA Stoner - Plos one, 2009 - journals.plos.org
Background Several anti-viral drugs have demonstrated efficacy in preventing
Cytomegalovirus (CMV) infections in solid organ transplant (SOT) patients. The recently …
Cytomegalovirus (CMV) infections in solid organ transplant (SOT) patients. The recently …
[HTML][HTML] Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R-solid organ transplant recipients
A Humar, C Paya, MD Pescovitz, E Dominguez… - American Journal of …, 2004 - Elsevier
Despite prophylaxis, cytomegalovirus (CMV) disease is common in donor seropositive
(D+)/recipient seronegative (R-) transplant patients after cessation of prophylaxis. Early …
(D+)/recipient seronegative (R-) transplant patients after cessation of prophylaxis. Early …
Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized …
N Singh, DJ Winston, RR Razonable, GM Lyon… - Jama, 2020 - jamanetwork.com
Importance Despite the use of a cytomegalovirus (CMV) prevention strategy of antiviral
prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive …
prophylaxis for high-risk CMV-seronegative liver transplant recipients with seropositive …
Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset …
N Singh, C Wannstedt, L Keyes, T Gayowski… - …, 2005 - journals.lww.com
Background. The efficacy of valganciclovir used as preemptive therapy for cytomegalovirus
(CMV) disease in liver transplant recipients is not known. Methods. Between 1996 and 2004 …
(CMV) disease in liver transplant recipients is not known. Methods. Between 1996 and 2004 …
Posttransfusion cytomegalovirus infections.
GE Tegtmeier - Archives of pathology & laboratory medicine, 1989 - europepmc.org
Prospective studies of transfused immunocompetent patients in the 1960s and early 1970s
showed high rates of cytomegalovirus (CMV) infection, ranging from 16% to 67%. Similar …
showed high rates of cytomegalovirus (CMV) infection, ranging from 16% to 67%. Similar …
Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial
CV Paya, JA Wilson, MJ Espy, IG Sia… - The Journal of …, 2002 - academic.oup.com
The use of postdetection antiviral treatment of cytomegalovirus (CMV) as a strategy to
prevent infection and disease in solid-organ transplant patients has not been evaluated by …
prevent infection and disease in solid-organ transplant patients has not been evaluated by …
[HTML][HTML] Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation
JF Camargo, KV Komanduri - Hematology/oncology and stem cell therapy, 2017 - Elsevier
Despite the refinements in molecular methods for the detection of cytomegalovirus (CMV)
and the advent of highly effective preemptive strategies, CMV remains a leading cause of …
and the advent of highly effective preemptive strategies, CMV remains a leading cause of …